EGA
LFCR icon

Eagle Global Advisors’s Lifecore Biomedical LFCR Stock Holding History

Eagle Global Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,870
Closed -$161K – 311
2017
Q2 		$161K Buy
+10,870
New +$151K ﹤0.01% 401

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Eagle Global Advisors's LFCR Position: Q3 2017 in Review

Eagle Global Advisors sold out of Lifecore Biomedical (LFCR) in Q3 2017, closing a stake of 10,870 shares — an estimated $161K sold.

Eagle Global Advisors first reported a position in LFCR in Q2 2017 and held it in 1 quarter. The position peaked at $161K in Q2 2017. 95 funds tracked by Wall St. Rank hold LFCR as of Q3 2017.

  • Eagle Global Advisors reported no remaining Lifecore Biomedical position as of Q3 2017 after selling out during the quarter.
  • Eagle Global Advisors sold 10,870 Lifecore Biomedical shares in Q3 2017, an estimated $161K.
  • Eagle Global Advisors first reported a position in Lifecore Biomedical in Q2 2017 and held it in 1 quarter.
  • Eagle Global Advisors's Lifecore Biomedical position peaked at $161K in Q2 2017.
  • 95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2017.

Based on Eagle Global Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.